Breast cancer resistance protein ( BCRP ) inhibitor

Details Breast cancer resistance protein ( BCRP ) inhibitor Breast cancer resistance protein ( BCRP ) inhibitor

2008-05-13

2008-05-13

Crane, L. E. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S402000

Reexamination Certificate

active

07371773

ABSTRACT:
The invention provides a drug which inhibits BCRP.A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1):[wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH3group); a cyano group (—CN group); a formyl group (—CHO group), —COOR1(R1is hydrogen or C1-C4 alkyl), —O(CH2)nCOOR2(n=1−7: R2is hydrogen or C1-C4 alkyl), —OOCCH2CH2COOR3(R3is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., —OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

REFERENCES:
patent: 3151148 (1964-09-01), Hughes et al.
patent: 5525632 (1996-06-01), Obsumi et al.
patent: 5731353 (1998-03-01), Ohsumi et al.
patent: 6992106 (2006-01-01), Morinaga et al.
patent: 2006/0128636 (2006-06-01), Yamazaki et al.
patent: 0 640 586 (1995-03-01), None
patent: 0 641 767 (1995-03-01), None
patent: 0 731 085 (1996-09-01), None
patent: 1 068 870 (2001-01-01), None
patent: 93/19746 (1993-10-01), None
patent: 99/07668 (1999-02-01), None
patent: 99/40056 (1999-08-01), None
Yoo et al., “Synthesis of an Estrogen Receptor β-Selective Radioligand: . . . ,” Journal of Medicinal Chemistry, 48(20), 6366-6378 (2005); Web published on Sep. 13, 2005.
Yoo et al., “Synthesis of an Estrogen Receptor β-Selective Radioligand: . . . ,” □□Journal of Medicinal Chemistry, 48(20), 6366-6378 (2005); Web published on Sep. 13, 2005.
Dore et al., “Antitumor Chemotherapy and Synthesis of Natural Antitumor Agents. VI. Cycotoxic Antitumor Activity of Trans-[alpha]-stilbenes in vitro and Antitumor Activity in vivo Against Krebs II Ascites Carcinoma,” J. de Pharmacia de Belgique, 28(1), 3-23 (1973); only Caplus abstract supplied, see structure at the top of p. No. 126.
Gilbert et al. “Study of the Effects of Basic Di- and Tri-phenyl Derivatives on Malignant Cell Proliferation: An Example of the Application of Correspondence Factor Analysis to Structure-Activity Relationships (SAR)”, Quant. Struct-Act. Relat., vol. 13, pp. 262-274 1994.
Ohsumi et al. “Novel Combretastatin Analogues Effective against Murine Solid Tumors: Design and Structure-Activity Relationships”, J. Med. Chem., vol. 41, pp. 3022-3032 1998.
F. Michel, et al., “The Effect of Various Acrylonitriles and Related Compounds on Prostaglandin Biosynthesis”, Prostaglandins, XP-002365729, vol. 27, No. 1, Jan. 1984, pp. 69-84.
Derwent Publications, AN 1993-340587, XP-002365731, JP 05-249517, Sep. 28, 1993.
J.T. Stewart, “Synthesis and Biological Evaluation of Substituted α-Phenylcinnamonitriles”, Journal of Pharmaceutical Sciences, XP-008059392, vol. 60, No. 8, Aug. 1971, pp. 1244-1245.
U.S. Appl. No. 11/909,805, filed Sep. 27, 2007, Yamazaki et al.
Sato et al, Cancer Research, 1991, 51, pp. 2420-2424.
Miyamoto et al, Cancer Research, 1993, 53, pp. 1555-1559.
Newman et al, Cancer Research, 2000, 60, pp. 2964-2972.

Affiliated with

Also associated with

Rating

Breast cancer resistance protein ( BCRP ) inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Breast cancer resistance protein ( BCRP ) inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breast cancer resistance protein ( BCRP ) inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2779841